PHARMACY

Deal complete, McKesson owns more than 75% of Celesio

BY Michael Johnsen

SAN FRANCISCO — McKesson on Thursday confirmed that it has completed the previously announced agreement with Franz Haniel & Cie. GmbH to acquire their entire holding of Celesio shares. McKesson also confirmed it has completed the previously announced agreement with an affiliate of Elliott Management to acquire Celesio convertible bonds.  

McKesson now exceeds 75% ownership of Celesio shares on a fully diluted basis.

The deal places McKesson on par with its competitors in terms of generic sourcing. The McKesson-Celesio deal is expected to generate a combined generic purchasing power of between $9.5 billion and $11.5 billion, according to an analysis by FBR Capital Markets. A similar analysis of the respective purchasing power of CVS Caremark and Cardinal Health has their combined purchasing power coming in between $9.5 billion and $11.5 billion. According to FBR, the Walgreens-Amerisource-Bergen-ABC Consortium has about $12 billion in combined generic purchasing power.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

PHARMACY

Sandoz launches generic Hectorol

BY Ryan Chavis

PRINCETON, N.J. — Sandoz announced the launch of doxercalciferol injection vials, the first generic version of Genzyme’s Hectorol. Doxercalciferol injection vials are used for the treatment of secondary hyperparathyroidism in patients with chronic kidney disease on dialysis.

“Sandoz is pleased to be the first company to market a high quality, affordable generic version of this important product to dialysis patients in the US,” Peter Goldschmidt, President of Sandoz, said.  

The company will market the drug in 4 mcg/2 mL single-dose vials.

 

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

PHARMACY

Report: Market for electronic health records to reach $17 billion by 2017

BY Michael Johnsen

LONDON — The market for electronic health and medical records is set to experience rapid growth over the coming years, with EMR peer group value estimated to climb from approximately $10.6 billion in 2012 to $17 billion by 2017, at a compound annual growth rate of 9.8%, according to research and consulting firm GlobalData.

The company’s new report estimates that McKesson had the largest Healthcare Information Technology Software and Services revenue in 2012, with $3.3 billion, placing it as the EMR market leader. McKesson is followed by Cerner and Allscripts, which achieved revenues of $2.7 billion and $1.5 billion, respectively.

According to GlobalData, this rapid EMR market growth is due to incentives offered under the American Relief and Recovery Act of 2009, which delivers opportunities for providers to transform unstructured, paper-based data into electronic digitized information that can be shared across the entire care industry.

“Physicians are selecting and implementing EMRs that meet federal requirements for meaningful use, and which also fit their practices and provide opportunities to enhance productivity, capture profits and improve clinical outcomes," stated Adam Dion, GlobalData’s analyst covering industry dynamics. “With the ever-changing world of healthcare regulations and reimbursement schedules, hospitals and health systems need solutions with the flexibility to handle diverse billing needs.”

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES